These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38213139)

  • 1. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma.
    Zhang Y; Yan HJ; Wu J
    Curr Cancer Drug Targets; 2024; 24(7):681-700. PubMed ID: 38213139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
    Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
    J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.
    Johnson C; Huynh V; Hargrove L; Kennedy L; Graf-Eaton A; Owens J; Trzeciakowski JP; Hodges K; DeMorrow S; Han Y; Wong L; Alpini G; Francis H
    Am J Pathol; 2016 Jan; 186(1):123-33. PubMed ID: 26597881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
    Minini M; Fouassier L
    Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment.
    Czekay RP; Higgins CE; Aydin HB; Samarakoon R; Subasi NB; Higgins SP; Lee H; Higgins PJ
    Cells; 2024 May; 13(10):. PubMed ID: 38786020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of Cholangiocarcinoma Immune Biology.
    Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
    Ravichandra A; Bhattacharjee S; Affò S
    Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis.
    Thanee M; Loilome W; Techasen A; Namwat N; Boonmars T; Pairojkul C; Yongvanit P
    Asian Pac J Cancer Prev; 2015; 16(7):3043-50. PubMed ID: 25854403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma.
    Lewinska M; Zhuravleva E; Satriano L; Martinez MB; Bhatt DK; Oliveira DVNP; Antoku Y; Keggenhoff FL; Castven D; Marquardt JU; Matter MS; Erler JT; Oliveira RC; Aldana BI; Al-Abdulla R; Perugorria MJ; Calvisi DF; Perez LA; Rodrigues PM; Labiano I; Banales JM; Andersen JB
    Gastroenterology; 2024 May; 166(5):886-901.e7. PubMed ID: 38096955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
    Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
    Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells.
    Thongchot S; Ferraresi A; Vidoni C; Loilome W; Yongvanit P; Namwat N; Isidoro C
    Cancer Lett; 2018 Aug; 430():160-171. PubMed ID: 29802929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.